Medicine
Tecartus 2000000/68 mL injectable suspension
Tecartus 2000000/68 mL injectable suspension is a prescription medicine containing Brexucabtagene autoleucel for intravenous use, marketed by Kite Pharma, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
At the treatment center, store TECARTUS frozen at ≤ -120°C (in a mechanical…
Key facts
- Active ingredient (INN)
- Brexucabtagene autoleucel
- Brand
- Tecartus
- Strength
- 2000000/68 mL
- Dosage form
- Injectable suspension
- Route
- Intravenous
- Packs
- 1 bag
- Marketing authorisation holder
- Kite Pharma
- Manufacturer
- Kite Pharma
- Origin register
- US FDA, United States
- Storage
- At the treatment center, store TECARTUS frozen at ≤ -120°C (in a mechanical freezer or in the vapor phase of liquid nitrogen) up to the labeled expiration date. TECARTUS may be transferred from vapor phase of liquid nitrogen to mechanical freezer storage at ≤ -120°C only once and cannot be transferred back. TECARTUS is supplied in a liquid nitrogen dry shipper at ≤ -150°C.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L01X Cancer medicines (antineoplastics), subgroup L01X
- HS code (indicative)
- 3002.51Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 24 July 2020
- Identifiers
- RxCUI 2387347, 2387352, 2572002 +1DailyMed set ID a16108c2-7ca7-45af-965e-54bda4713022NDC 71287-219Application BLA125703
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 bag in 1 package / 68 mL in 1 bag | 71287-219-02 | Kite Pharma | 24 July 2020 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Brexucabtagene autoleucel
Clinical summary
Brexucabtagene autoleucel is a prescription medicine indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL), among other approved uses. It is available as injectable suspension for intravenous use. MedsAcross supplies Brexucabtagene autoleucel for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Brexucabtagene autoleucelFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- TECARTUS prescribing information (Kite Pharma) · U.S. National Library of Medicine, DailyMed
- Tecartus: European public assessment report (EPAR) · European Medicines Agency
Need Tecartus 2000000/68 mL injectable suspension for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.